Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

@article{Hyrich2007OutcomesAS,
  title={Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.},
  author={Kimme L Hyrich and Mark Lunt and Kath D. Watson and Deborah P. M. Symmons and Alan Jonathan Silman},
  journal={Arthritis and rheumatism},
  year={2007},
  volume={56 1},
  pages={13-20}
}
OBJECTIVE Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti-tumor necrosis factor (anti-TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti-TNF agent, although the benefits of switching are unknown. The present study was undertaken to compare drug continuation rates between the… CONTINUE READING